Shuttle Pharmaceuticals | 3: Initial statement of beneficial ownership of securities-Director Tung Joseph
Shuttle Pharmaceuticals | 3: Initial statement of beneficial ownership of securities-Director Nabyt Oleh
Shuttle Pharmaceuticals | 3: Initial statement of beneficial ownership of securities-Director Scorsis George
Shuttle Pharmaceuticals | PRE 14A: Preliminary proxy statements relating to merger or acquisition
Shuttle Pharmaceuticals | 8-K: Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering
Shuttle Pharmaceuticals | 424B3: Prospectus
Shuttle Pharmaceuticals | 8-K: Shuttle Pharmaceuticals Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities
Shuttle Pharmaceuticals | EFFECT: Others
Shuttle Pharmaceuticals | S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)
Shuttle Pharmaceuticals | 8-K: Revolving Loan Agreement
Shuttle Pharmaceuticals | 424B3: Prospectus
Shuttle Pharmaceuticals | 424B3: Prospectus
Shuttle Pharmaceuticals | 424B3: Prospectus
Shuttle Pharmaceuticals | 8-K: Amendment Agreement
Shuttle Pharmaceuticals | 8-K: Shuttle Pharma Provides Corporate Update and Reports 2024 Results
Shuttle Pharmaceuticals | 10-K: FY2024 Annual Report
Shuttle Pharmaceuticals | SCHEDULE 13G: Others
Shuttle Pharmaceuticals | S-1: General form for registration of securities under the Securities Act of 1933
Shuttle Pharmaceuticals | 5/A: Annual statement of changes in beneficial ownership of securities (Amendment)-Director Schafer Joshua
Shuttle Pharmaceuticals | 5/A: Annual statement of changes in beneficial ownership of securities (Amendment)-Director Richards Steven M